Figure 1.
Anti–SARS-CoV-2 antibody response in patients with CLL and healthy control subjects. (A-B) Distribution of individual responses in patients with CLL (n = 52) and sex- and age-matched control subjects (n = 52). Each column represents the level of antibodies in individual patients (red bars indicate treatment naive, green bar indicates on-therapy, blue bars indicate off-therapy in remission, and purple bars indicate off-therapy in relapse) in panel A and in individual healthy control subjects (red bars) in panel B. (C) Response rate in patients with CLL (n = 52) and sex- and age-matched control subjects (n = 52). (D) Anti–SARS-CoV-2 antibody levels in patients with CLL (n = 52) and sex- and age-matched control subjects (n = 52).

Anti–SARS-CoV-2 antibody response in patients with CLL and healthy control subjects. (A-B) Distribution of individual responses in patients with CLL (n = 52) and sex- and age-matched control subjects (n = 52). Each column represents the level of antibodies in individual patients (red bars indicate treatment naive, green bar indicates on-therapy, blue bars indicate off-therapy in remission, and purple bars indicate off-therapy in relapse) in panel A and in individual healthy control subjects (red bars) in panel B. (C) Response rate in patients with CLL (n = 52) and sex- and age-matched control subjects (n = 52). (D) Anti–SARS-CoV-2 antibody levels in patients with CLL (n = 52) and sex- and age-matched control subjects (n = 52).

Close Modal

or Create an Account

Close Modal
Close Modal